HPLC-UV method for quantification of favipiravir in pharmaceutical formulations

Abstract

Favipiravir (FVP), a pyrazine analog, has shown antiviral activity against a wide variety of viruses. It is considered to be worth further investigation as a potential candidate drug for COVID-19. It is not officially available in any pharmacopoeia. A rapid, simple, precise, accurate, and isocratic high performance liquid chromatography (HPLC) method has been developed for routine quality control of favipiravir in pharmaceutical formulations. Separation was carried out by C18 column. The mobile phase was a mixture of 50 mM potassium dihydrogen phosphate (pH 2.3) and acetonitrile (90:10, v/v) at a flow rate of 1 mL min−1. The ultraviolet (UV) detection and column temperature were 323 nm, and 30 °C, respectively. The run time was 15 min under these chromatographic conditions. Excellent linear relationship between peak area and favipiravir concentration in the range of 10–100 μg mL−1 has been observed (r2, 0.9999). Developed method has been found to be sensitive (limits of detection and quantification were 1.20 μg mL−1 and 3.60 μg mL−1, respectively), precise (the interday and intraday relative standard deviation (RSD) values for peak area and retention time were less than 0.4 and 0.2%, respectively), accurate (recovery, 99.19–100.17%), specific and robust (% RSD were less than 1.00, for system suitability parameters). Proposed method has been successfully applied for quantification of favipiravir in pharmaceutical formulations.

First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode

“…As it was mentioned earlier, a survey of the literature revealed that there are only two studies for the quantitative determination of favipiravir. In the first attempt, it was reported the use of high performance liquid chromatography with UV detection [ 17 ]. LOD value equaled to 1.20 mg mL ‒1 has been estimated in a mobile phase consisting potassium dihydrogen phosphate 50 mM (pH 2.3) and acetonitrile (90:10, v/v).…”

“…Apart from these requirements, such studies in biological matrices will assist in the development of new drugs [ 16 ]. Survey of the literature revealed that only two studies have been made on the quantification of favipiravir by using high performance liquid chromatography coupled with ultraviolet (UV) detection [ 17 ], and spectrofluorimetric method [ 18 ].…”

A novel, rapid and simple UPLC–MS/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study

“…It is being used now as a possible treatment for COVID-19 infection (NCT, 2020;Pilkington et al, 2020;Radhakrishnan et al, 2020).Searching the literature there is no method for determination of FAV in human plasma. Only one HPLC method was described for quantification in pharmaceutical formulations (Bulduk, 2021). The aim of this work was to develop a sensitive, rapid and reproducible method for estimation of FAV in human plasma to allow high output analysis, which is required for a pharmacokinetic and bioequivalence study.…”

Analytical Method Development and Validation and Forced Degradation Stability-Indicating Studies of Favipiravir by RP-HPLC and UV in Bulk and Pharmaceutical Dosage Form

“…The run time was 15 min under these chromatographic conditions. Excellent linear relationship between peak area and Favipiravir concentration in the range of 10-100mg/ml has been observed [6].…”